Do you want to read an article? Please log in or register.
Identification of progressive pulmonary fibrosis: consensus findings from a modified Delphi study
Pulmonary FibrosisFurther Publications
RECOMMENDED
Related content
RECOMMENDED
COPD
Identification and management of cardiopulmonary risk in patients with COPD: a multidisciplinary consensus and modified Delphi study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur J Prev Cardiol
Gale CP, Hurst JR, Hawkins NM, Bourbeau J, Han MK, Lam CSP, Marciniuk DD, Price D, Stolz D, Gluckman T, Zieroth S, Nadarajah R, Young RP, Singh D, Martinez FJ, Berg DD, Bhutani M, Global Working Group on Cardiopulmonary Risk
doi: 10.1093/eurjpc/zwaf119
RECOMMENDED
Interstitial Lung Disease
Progressive Early Interstitial Lung Abnormalities in Persons At-Risk for Familial Pulmonary Fibrosis: A Prospective Cohort Study
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Am J Respir Crit Care Med
Salisbury ML, Markin C, Fadely T, Guttentag AR, Humphries SM, Lynch DA, Kropski JA, Blackwell TS
doi: 10.1164/rccm.202403-0524OC
RECOMMENDED
Further Publications
Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Ther Adv Respir Dis
Mira-Avendano I, Kaye M
doi: 10.1177/17534666241266343
RECOMMENDED
Pulmonary Fibrosis
Effect of Admilparant, an LPA1 Antagonist, on Disease Progression in Pulmonary Fibrosis
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Chest
Kreuter M, Maher TM, Wuyts WA, Valenzuela C, Hamblin M, Kim S, Patel A, Elpers B, Richeldi L
doi: 10.1016/j.chest.2025.04.003
RECOMMENDED
Interstitial Lung Disease
Unsupervised Exercise in Interstitial Lung Disease: A Delphi Study to Develop a Consensus Preparticipation Screening Tool for Lymphangioleiomyomatosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Child CE, Ho LA, Lachant D, Gupta N, Moss J, Jones A, Krishna R, Holland AE, Han MK, McCarthy C, Ataya A, Baqir M, Dilling D, Swigris J, Swenson ER, Brown MB
doi: 10.1016/j.chest.2024.06.3803
Pulmonary Fibrosis
Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation
Lancet Respir Med
Alonso-González A, Jáspez D, Lorenzo-Salazar JM, Ma SF, Strickland E, Mychaleckyj J, Kim JS, Huang Y, Adegunsoye A, Oldham JM, Stewart I, Molyneaux PL, Maher TM, Wain LV, Allen RJ, Gisli Jenkins R, Kropski JA, Yaspan B, Blackwell TS, Zhang D, Garcia CK, Martinez FJ, Noth I, Flores C
doi: 10.1016/S2213-2600(25)00045-1
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Association Between Calcium Channel Blocker Use and the Risk of Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: A Longitudinal Cohort Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Jang HJ, Seong YM, Jeong J, Huh JY, Kim JH, Kim KH, Park JH, Choi WI
doi: 10.1016/j.rmed.2025.107939
RECOMMENDED
Pulmonary Fibrosis
Identifying outcome domains to establish a core outcome set for progressive pulmonary fibrosis: a scoping review
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir Rev
Delameillieure A, Somogyi V, Schenk S, Toreyin N, Stenzel N, Van Bulck L, Breuls S, Kreuter M, Wuyts WA, Mogulkoc N, Boyd J, Jones S, Galvin L, Dobbels F, COCOS-IPF consortium
doi: 10.1183/16000617.0133-2024
Pulmonary Fibrosis
Antifibrotic drug treatment of patients with idiopathic pulmonary fibrosis in Sweden: A registry-based observational study
Chron Respir Dis
Carlson L, Kalafatis D, Pesonen I, Magnusson JM, Skold M
doi: 10.1177/14799731241299443